Articles by Alexandra K. Golant, MD
In the final episode, “Improving Access to Advanced Nonsteroidal Topical Therapies in Inflammatory Dermatoses,” the panelists explored practical strategies for overcoming barriers to advanced nonsteroidal topical therapies and discussed how these treatments are reshaping long-term disease management. Building on the consensus statement addressing affordable access, the expert faculty examine the challenges patients and clinicians face when attempting to obtain newer targeted topical treatments and review resources that may help improve treatment accessibility.
This episode, titled “The Evolving Role of Nonsteroidal Topicals in Inflammatory Dermatoses,” features panelists discussing the efficacy of advanced targeted topical therapies and their growing role in the long-term management of inflammatory skin diseases. Building on previous discussions of safety and tolerability, the expert faculty review evidence supporting both the short-term and long-term effectiveness of nonsteroidal topical treatments across multiple inflammatory dermatoses.
In “The Safety of Advanced Topical Therapies in Inflammatory Dermatoses,” our panel explores the consensus statements evaluating the short- and long-term safety of advanced targeted topical therapies for inflammatory skin diseases. The expert faculty review the growing body of clinical trial evidence supporting several nonsteroidal topical treatments, including roflumilast, tapinarof, ruxolitinib, crisaborole, and delgocitinib, and discuss how these therapies have expanded treatment options across multiple inflammatory dermatoses.
In this episode, “Understanding Corticosteroid-Related Medical-Legal Risks in Inflammatory Dermatoses,” the expert faculty explore the consensus statement addressing the medical-legal considerations associated with corticosteroid prescribing and the importance of responsible corticosteroid stewardship in clinical practice. The panel discusses how growing awareness of corticosteroid-related adverse events has implications not only for patient safety, but also for clinician accountability and risk management.
This episode, titled “Moving Beyond Long-Term Topical Corticosteroid Use in Inflammatory Dermatoses,” features panelists discussing the evolving role of topical corticosteroids in the management of chronic inflammatory skin diseases. Building on the consensus statement that topical corticosteroids should not be routinely prescribed for long-term use in chronic conditions, the expert faculty examine the distinction between acute flare management and long-term disease control.
In “Reducing Treatment Burden in Inflammatory Dermatoses,” our panel explores the practical challenges associated with managing chronic inflammatory skin diseases using multiple topical corticosteroids. Building on the consensus statement that the use of different corticosteroids for different body areas can create significant burden for patients, the expert faculty discuss how increasingly complex treatment regimens can negatively impact adherence, disease control, and the overall patient experience.
In this episode, “Understanding Corticosteroid Risks in Inflammatory Dermatoses,” the expert faculty explore the key findings from a recent consensus paper evaluating the risks associated with topical and systemic corticosteroid therapy and the role of advanced targeted topical treatments in inflammatory skin diseases. The panel reviews the methodology behind the expert consensus process, including the comprehensive literature review and evidence-based approach used to develop recommendations for clinical practice.
Welcome back to another Dermatology Times Between the Lines series. In this episode titled, “Rethinking Long-Term Management of Inflammatory Dermatoses,” the expert faculty discuss the chronic, relapsing nature of inflammatory skin diseases and how advances in our understanding of underlying inflammation have influenced treatment goals. The panel explores commonly encountered inflammatory dermatoses, including atopic dermatitis, psoriasis, and seborrheic dermatitis, and examines how durable disease control has become an increasingly important objective in clinical practice.
Experts discuss effective strategies for managing atopic dermatitis, emphasizing the importance of treatment adherence and quality of life improvements.
Explore effective management strategies for pediatric atopic dermatitis, focusing on treatment options and patient experiences for optimal care.
Parents of children with chronic skin conditions seek guidance on managing flares and long-term treatment strategies for better outcomes.
Experts discuss effective eczema management for young children, emphasizing treatment options, parental education, and the importance of long-term care strategies.
A pediatric case highlights the challenges of managing severe atopic dermatitis in infants, emphasizing the need for effective treatment strategies.
An 18-month-old with severe atopic dermatitis experiences rapid flare-ups, prompting a discussion on treatment options and potential triggers.
Explore effective management strategies for atopic dermatitis in children, focusing on non-steroidal options and addressing parental concerns.
Healthcare professionals discuss effective educational strategies for managing chronic skin conditions, emphasizing proactive treatment and patient understanding.
Healthcare professionals discuss effective educational strategies for managing chronic skin conditions, emphasizing proactive treatment and patient understanding.
Explore the innovative role of PDE4 inhibitors in treating atopic dermatitis, highlighting breakthroughs in topical therapies and their efficacy.
Explore the innovative role of PDE4 inhibitors in treating atopic dermatitis, highlighting breakthroughs in topical applications and their efficacy.
Healthcare professionals discuss the balance of safety and effectiveness in prescribing topical steroids and non-steroidal treatments for pediatric patients.
Explore the evolving landscape of pediatric atopic dermatitis treatment, focusing on innovative therapies and strategies to break the steroid cycle.
Experts explore innovative treatments for pediatric atopic dermatitis, emphasizing non-steroidal options and early intervention for better long-term management.
Alexandra Golant, MD discusses how addressing severe, recalcitrant atopic dermatitis remains the most pressing unmet need, with emerging biologics, oral JAK inhibitors, and combination therapies offering promising new approaches for these challenging cases.
Alexandra Golant, MD discusses how cost considerations, insurance barriers, formulary restrictions, and effective caregiver education about proper application will significantly impact the widespread adoption of ruxolitinib cream in pediatric dermatology practice.
Alexandra Golant, MD discusses how regulatory challenges, ethical considerations in pediatric clinical trials, and limited pharmacokinetic data present significant hurdles for pediatric treatment approvals, while topical ruxolitinib cream's targeted mechanism of action and steroid-sparing benefits make it a meaningful addition for younger children.
Alexandra Golant, MD discusses how the availability of topical ruxolitinib data in children as young as age 2 could potentially shift pediatric atopic dermatitis treatment guidelines by providing a non-steroidal alternative with a favorable safety profile.
Alexandra Golant, MD, discusses how advancements in pediatric atopic dermatitis (AD) treatment, including topical Janus kinase (JAK) inhibitors like ruxolitinib, may reshape guidelines, yet hurdles remain in regulatory approval, safety data, and accessibility. Adoption depends on efficacy, cost, insurance, and caregiver education. Unmet needs persist in long-term disease control and tailored pediatric options.
Eli Lilly recently hosted a panel discussion with Olympic athlete Suni Lee to discuss the importance of finding a dermatologist who understands the burden of AD.
Dr. Alexandra Golant shares invaluable practice pearls for optimizing the management of hand and foot atopic dermatitis with the use of systemic treatments.
Dr Alexandra Golant discusses managing multiple conditions in a 17-year-old African American waitress, highlighting the complexities of treating moderate-to-severe atopic dermatitis alongside severe acne and oral contraceptives. She also addresses potential drug interactions, focusing on the safety of dupilumab in systemic treatment.
